Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
      • Neuroimmunology: To Sense and Protect
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

IL-33 Receptor ST2 Amplifies the Expansion of NK Cells and Enhances Host Defense during Mouse Cytomegalovirus Infection

Tsukasa Nabekura, Jean-Philippe Girard and Lewis L. Lanier
J Immunol June 15, 2015, 194 (12) 5948-5952; DOI: https://doi.org/10.4049/jimmunol.1500424
Tsukasa Nabekura
*Department of Microbiology and Immunology and the Cancer Research Institute, University of California, San Francisco, San Francisco, CA 94143;
†Life Science Center of Tsukuba Advanced Research Alliance, University of Tsukuba, Ibaraki 305-8577, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Philippe Girard
‡Centre National de la Recherche Scientifique and Université de Toulouse, Institut de Pharmacologie et de Biologie Structurale, F-31077 Toulouse, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lewis L. Lanier
*Department of Microbiology and Immunology and the Cancer Research Institute, University of California, San Francisco, San Francisco, CA 94143;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

NK cells provide important host defense against viruses and can differentiate into self-renewing memory NK cells after infection, alloantigen stimulation, and cytokine stimulation. In this study, we investigated the role of the IL-33 receptor ST2 in the differentiation of NK cells during mouse CMV (MCMV) infection. Although ST2-deficient (Il1rl1−/−) Ly49H+ NK cells develop normally and differentiate into memory cells after MCMV infection, naive and memory Il1rl1−/− Ly49H+ NK cells exhibited profound defects in MCMV-specific expansion, resulting in impaired protection against MCMV challenge. Additionally, IL-33 enhanced m157 Ag-specific proliferation of Ly49H+ NK cells in vitro. Thus, an IL-33/ST2 signaling axis in NK cells contributes to host defense against MCMV.

Introduction

Natural killer cells recognize abnormal or allogeneic cells by using a repertoire of receptors that regulates their activation and effector functions (1). NK cells have adaptive immune features, which include differentiation into self-renewing memory cells after exposure to mouse CMV (MCMV), haptens, cytokines, and alloantigens (2-6). In humans, NKG2Chigh NK cells have been identified as memory NK cells based on their specific expansion and persistence for months following human CMV infection (3, 7, 8). Mouse NK cells expressing Ly49H, which recognizes the m157 MCMV glycoprotein on infected cells (9), undergo clonal expansion, contraction, and differentiation into memory cells after MCMV infection (5). The DAP12 and DAP10 adaptor proteins and the costimulatory DNAM-1 receptor are required for optimal expansion of Ly49H+ NK cells and their differentiation into memory cells (5, 10). IL-12 is essential for both expansion and memory generation (11); however, the roles of other cytokines for adaptive immune responses mediated by NK cells are largely unknown.

IL-33, a member of the IL-1 cytokine family (12), is expressed constitutively by endothelial and epithelial cells and by fibroblastic reticular cells (FRCs) in secondary lymphoid organs (13). It is released upon tissue damage and necrosis, thus acting as an early inducer of inflammation, and it exacerbates Th2 immune responses in mouse models of arthritis and asthma (14). Binding of IL-33 to its receptor ST2 induces MyD88-dependent activation of NF-κB and MAPK (14). ST2 is expressed on many immune cells (12, 15, 16), and the IL-33/ST2 signaling pathway augments IL-12–induced IFN-γ production by NK cells (15, 16). ST2 is essential for control of coxsackievirus B5-induced pancreatitis by enhancing IFN-γ production by NK cells, which is associated with viral clearance (17). In the present study, we investigated the role of the IL-33/ST2 signaling axis in the adaptive immune response of NK cells during MCMV infection.

Materials and Methods

Mice and MCMV

C57BL/6 and congenic CD45.1+ C57BL/6 mice were purchased from the National Cancer Institute. C57BL/6 ST2-deficient (Il1rl1−/−) mice (18), provided by Dr. S. Akira (Osaka University), IL-33–lacZ gene trap reporter (Il33−/−) mice (13), and Ly49H-deficient (Klra8−/−) mice (19), provided by Dr. S. Vidal (McGill University), and DAP12-deficient (Tyrobp−/−) mice (20) were maintained in accordance with the guidelines of the University of California San Francisco Institutional Animal Care and Use Committee. CD45.1+ wild-type (WT) and CD45.2+ Il1rl1−/− mixed bone marrow (BM) chimeric mice were generated as described (5). Smith strain MCMV was prepared as described (6). Mice were infected by i.p. injection of 1–5 × 105 PFU.

NK cell enrichment and adoptive transfer

NK cells were enriched by Ab-coated magnetic bead selection or flow cytometry as described (10). Ten million splenocytes or 2 × 105 Ly49H+ NK cells from mixed BM chimeric mice were injected i.v. into Ly49H-deficient mice on the day before infection. In some experiments, splenocytes were labeled with 10 μM CellTrace Violet (Invitrogen).

Flow cytometry

Fc receptors were blocked with 2.4G2 mAb before staining with the indicated mAbs or isotype-matched control Abs (BD Biosciences, eBioscience, or BioLegend). Samples were acquired on an LSR II (BD Biosciences) and analyzed with FlowJo software (Tree Star).

In vitro stimulation and proliferation of NK cells

One million splenocytes from mixed BM chimeric mice were incubated in 96-well tissue culture plates coated with anti-NKp46 (29A1.4) as described (5), or with 10 ng/ml mouse IL-12 plus 10 ng/ml mouse IL-18 (R&D Systems), 10 ng/ml PMA plus 1 μg/ml ionomycin (Sigma-Aldrich), or cocultured with 1 × 105 RMA or m157-transfected RMA cells as described (6). One million CellTrace Violet–labeled splenocytes were cocultured with 1 × 105 RMA or m157-transfected RMA cells (fixed in 1% paraformaldehyde) in the absence or presence of 25 ng/ml mouse IL-33 (R&D Systems) and/or 10 ng/ml mouse IL-12 with 50 U/ml human IL-2 (National Cancer Institute) for 4 d at 37°C.

Viral load

Ten thousand naive or memory Ly49H+ NK cells were transferred separately into Ly49H-deficient or DAP12-deficient mice and infected with MCMV. Peripheral blood was collected on day 4 postinfection (p.i.), and the right lobe of liver and the spleen were homogenized in DMEM with 10% FCS on day 7 p.i. and DNA was isolated from these specimens. The copy number of MCMV IE1 gene in blood, spleen, and liver was determined as described (10). The copy number of MCMV IE1 gene in the spleen was calculated for the whole organ and the copy number of MCMV IE1 in the liver was adjusted for weight of the tissue.

IL-33 in splenic stromal cells

Splenic stromal cells were prepared as described with minor modifications (21). Spleens were digested with 0.2 U/ml dispase, 0.2 mg/ml collagenase D, and 0.1 mg/ml DNase I (Roche), and stromal cells were enriched by depletion with mAbs against CD4, CD8, CD11b, CD19, and Ter119, and magnetic separation with anti-rat IgG–coated beads (Qiagen). FRCs (CD31−gp38+), lymphatic endothelial cell (LEC)-like cells (CD31+gp38+), double-negative cells (CD31−gp38−), and blood endothelial cells (CD31+ gp38-) were gated on 7-aminoactinomycin D−CD45− cells and purified by flow cytometry. The relative quantity of IL-33 transcripts was determined by quantitative RT-PCR analysis using the following primers: Actb, forward, 5′-GGCTGTATTCCCCTCCATCG-3′, reverse, 5′-CCAGTTGGTAACAATGCCATGT-3′. Il33, forward, 5′-TCCAACTCCAAGATTTCCCCG-3′, reverse, 5′-CATGCAGTAGACATGGCAGAA-3′.

Statistical analysis

The Student t test was used to compare results. The Mann–Whitney U test was used to compare MCMV viral titers. Error bars represent SEM.

Results

ST2 is dispensable for NK cell development

To determine whether an intrinsic lack of ST2 affects NK cell development and function, we reconstituted lethally irradiated recipient mice with CD45.1+ WT and CD45.2+ Il1rl1−/− BM cells and allowed NK cells to reconstitute in the recipient mice for >5 wk. Equivalent frequencies of WT and Il1rl1−/− NK cells were detected in the blood, spleen, liver, and BM after reconstitution (data not shown). WT and Il1rl1−/− NK cells exhibited similar developmental stages and equivalently expressed KLRG1, NKG2D, Ly49H, Ly49C and/or Ly49I, Ly49G2, DNAM-1, NKp46, NK1.1, IL-2Rα, IL-2Rβ, and IL-7Rα (Fig. 1A and data not shown). Similar frequencies of WT and Il1rl1−/− NK cells degranulated and produced IFN-γ when cocultured with m157-transfected RMA cells, stimulated by crosslinking NKp46, cultured with IL-12 plus IL-18, and activated with PMA plus ionomycin (Fig. 1B). Similarly, NK cells in Il33−/− mice expressed NK receptors comparably to WT NK cells (data not shown).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Phenotype of Il1rl1−/− NK cells. (A) Developmental stages as determined by expression of CD11b, CD27, and NK receptors on WT (bold lines) and Il1rl1−/− (thin lines) NK cells, gating on TCRβ−NK1.1+ lymphocytes in the blood from mixed BM chimeric mice. Data are representative of three experiments (n = 2–3 mice/experiment). (B) Degranulation and IFN-γ production of WT (open bars) and Il1rl1−/− (filled bars) NK cells after in vitro stimulation. Data are representative of three experiments (n = 3–4 in each stimulation).

ST2 enhances NK cell expansion during MCMV infection

WT and Il1rl1−/− Ly49H+ NK cells were isolated from BM chimeric mice, adoptively transferred into Ly49H-deficient recipient mice, and infected with MCMV. During the early phase of infection, donor WT and Il1rl1−/− Ly49H+ NK cells were activated equivalently, as evidenced by upregulation of CD69 on day 1.5 p.i. and KLRG1 on day 7 p.i., and they produced similar amounts of IFN-γ on day 1.5 p.i. (Fig. 2A, 2B and data not shown). A similar frequency of Il1rl1−/− Ly49H+ NK cells stained for annexin V in uninfected and infected recipient mice, comparably to WT Ly49H+ NK cells (Fig. 2C). However, Il1rl1−/− Ly49H+ NK cells proliferated less than did WT Ly49H+ NK cells on day 3 p.i. (Fig. 2D, 2E). Consistent with the phenotype of Il1rl1−/− NK cells, Ly49H+ NK cells in Il33−/− mice activated, produced IFN-γ, and stained for annexin V early after infection comparably to WT mice (Fig. 2F–H). However, a smaller percentage of Ki67+Ly49H+ NK cells was observed in Il33−/− mice compared with WT mice (Fig. 2I, 2J). These findings demonstrate that ST2 and IL-33 are dispensable for activation, IFN-γ production, and survival of NK cells, but they augment expansion of Ly49H+ NK cells during MCMV infection.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

ST2 enhances Ly49H+ NK cell proliferation during MCMV infection. Ly49H+ NK cells (A and B) or CellTrace Violet–labeled splenocytes (C–E) from WT and Il1rl1−/− mixed BM chimeric mice were transferred into Ly49H-deficient mice and infected with 1 × 105 PFU MCMV. (A) CD69 and (B) IFN-γ on day 1.5 p.i., and (C) annexin V and (D) CellTrace Violet on day 3 p.i. of WT (bold lines) and Il1rl1−/− (thin lines) Ly49H+ NK cells in the spleen. Dark gray–shaded and light gray–shaded histograms represent naive WT and Il1rl1−/− Ly49H+ NK cells, respectively. Data are representative of two experiments (n = 3 mice/experiment). (E) Percentages of divided Ly49H+ NK cells were quantified. Data are pooled from two experiments (n = 6 mice). (F–J) WT and Il33−/− mice were infected with 5 × 105 PFU MCMV. (F) CD69 and (G) IFN-γ on day 1.5 p.i. and (H) annexin V and (I) Ki67 on day 3 p.i. of WT (bold lines) and Il33−/− (thin lines) Ly49H+ NK cells in the spleen. Dark gray–shaded and light gray–shaded histograms represent naive WT and Il33−/− Ly49H+ NK cells, respectively. Data are representative of two experiments (n = 2–4 mice/experiment). (J) Percentages of Ki67+ Ly49H+ NK cells were quantified. Data are pooled from two experiments (n = 6 mice). *p < 0.05.

ST2 enhances expansion of naive and memory Ly49H+ NK cells and control of MCMV

WT and Il1rl1−/− Ly49H+ NK cells from BM chimeric mice were adoptively transferred into Ly49H-deficient recipient mice and infected with MCMV. Il1rl1−/− Ly49H+ NK cells proliferated less than did WT Ly49H+ NK cells in the spleen and liver at the peak of the NK cell response on day 7 p.i. (Fig. 3A, 3B). Consistent with the phenotype of Il1rl1−/− Ly49H+ NK cells, Ly49H+ NK cells in Il33−/− mice had a defect in proliferation after the infection compared with WT mice (Fig. 3C). WT and Il1rl1−/− Ly49H+ NK cells adoptively transferred into Ly49H-deficient recipient mice generated a long-lived subset in the blood and spleen 1 mo p.i. with MCMV (Fig. 3D, 3E), although Il1rl1−/− Ly49H+ NK cells showed pronounced impairment in expansion in the blood on day 7 p.i. (Fig. 3D). These Il1rl1−/− Ly49H+ NK cells displayed a memory-associated phenotype characterized as CD11b+CD27−KLRG1highDNAM-1low, as described previously (5, 6, 10) (Fig. 3F). Memory Il1rl1−/− Ly49H+ NK cells that were isolated from infected mice and adoptively transferred into naive Ly49H-deficient recipients also expanded poorly when rechallenged with MCMV (Fig. 3G). Moreover, both naive and memory Il1rl1−/− Ly49H+ NK cells adoptively transferred into Ly49H-deficient mice or DAP12-deficient mice, which lack functionally competent Ly49H+ NK cells and are unable to control early replication of MCMV (5), showed a poor protective effect against MCMV challenge compared with WT Ly49H+ NK cells in the blood, spleen, and liver, consistent with the impaired proliferation of Il1rl1−/− Ly49H+ NK cells (Fig. 3H–J). Thus, ST2 is necessary not only for the optimal expansion of naive and memory Ly49H+ NK cells during MCMV infection, but also for efficient control of MCMV.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

ST2 and IL-33 augment expansion of naive and memory Ly49H+ NK cells and control of MCMV. (A and B) WT and Il1rl1−/− Ly49H+ NK cells from mixed BM chimeric mice were transferred into Ly49H-deficient mice and infected with 1 × 105 PFU MCMV. The number of Ly49H+ NK cells in the spleen (A) and liver (B) on day 7 p.i. is shown. Data are pooled from two experiments (n = 6 mice). (C) WT and Il33−/− mice were infected with 5 × 105 PFU MCMV. The number of Ly49H+ NK cells in the blood on day 7 p.i. is shown. Data are pooled from two experiments (n = 4 mice). (D and E) WT and Il1rl1−/− Ly49H+ NK cells were transferred into Ly49H-deficient mice and infected with MCMV. (D) The number of Ly49H+ NK cells in the blood is represented as the ratio relative to the number of Ly49H+ NK cells in the blood on day 0 (before infection). (E) The y-axis represents the number of memory Ly49H+ NK cells detected in the spleen on day 29 p.i. compared with the number of naive Ly49H+ NK cells adoptively transferred into recipient mice on day 0. Data are pooled from three experiments (n = 8 mice). (F) Phenotype of WT and Il1rl1−/− memory Ly49H+ NK cells on day 29 p.i. in the spleen. Bold and thin lines represent memory WT and Il1rl1−/− Ly49H+ NK cells, respectively. Dark gray–shaded and light gray–shaded histograms represent naive WT and Il1rl1−/− Ly49H+ NK cells, respectively. Data are representative of two experiments (n = 2–3 mice/experiment). (G) Memory Ly49H+ NK cells were isolated 29 d p.i., transferred into naive Ly49H-deficient mice, and infected with 1 × 105 PFU MCMV. Expansion of memory Ly49H+ NK cells in the spleen on day 7 after secondary infection is represented as the fold expansion relative to the number of memory Ly49H+ NK cells detected in the spleen of mice adoptively transferred with memory Ly49H+ NK cells but not infected. Data are pooled from three experiments (n = 9 mice). *p < 0.05, **p < 0.01 versus Il1rl1−/− or Il33−/−. (H–J) WT and Il1rl1−/− memory NK cells were purified 25–32 d p.i., and WT and Il1rl1−/− naive NK cells were purified from BM chimeric mice. WT and Il1rl1−/− naive and memory Ly49H+ NK cells were transferred separately into Ly49H-deficient or DAP12-deficient mice and infected with 1 × 105 PFU MCMV. The copy number of MCMV IE1 gene in the blood (H) on day 4 p.i. and in the spleen (I) and liver (J) on day 7 p.i. was analyzed by quantitative PCR. (H) Data were pooled from four experiments (n = 7–11 mice/group) and (I and J) data were pooled from two experiments (n = 4 mice/group). *p < 0.05, ***p < 0.005.

Splenic stromal cells upregulate IL-33 during MCMV infection

FRCs, a stromal cell subset in secondary lymphoid organs, constitutively express IL-33, and IL-33 is upregulated in inflamed tissues (13). We investigated whether stromal cell subsets modulate expression of IL-33 during MCMV infection. Frequencies of splenic stromal cell subsets, as determined by staining CD45− cells with CD31 and gp38, did not change dramatically during MCMV infection (data not shown). However, FRCs, LEC-like cells, and double-negative cells, but not blood endothelial cells, highly upregulated IL-33 transcripts in the early course of infection (Fig. 4).

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

FRCs and LEC-like cells upregulate IL-33 during MCMV infection. Splenic stromal cell subsets were purified and IL-33 transcripts were quantified by quantitative RT-PCR. Relative quantity of IL-33 transcripts in each stromal subset in infected mice with 5 × 105 PFU MCMV was represented as the ratio relative to the quantity in uninfected mice (day 0). Data were pooled from three experiments (n = 6 mice/day). *p < 0.05, **p < 0.01 versus day 0. BECs, blood endothelial cells; DN, double-negative.

IL-33 enhances m157-dependent proliferation of Ly49H+ NK cells

IL-33 synergizes with IL-12 for IFN-γ production by NK cells (15, 16). To address whether IL-33 has a direct effect on proliferation, WT and Il1rl1−/− Ly49H+ NK cells were cocultured with RMA or m157-transfected RMA cells in the absence or presence of IL-12 and IL-33 with a low dose IL-2. IL-33 had little impact on Ag nonspecific cell divisions of Ly49H+ NK cells induced by IL-2, or the m157-driven proliferation of Ly49H+ NK cells in the absence of IL-12 (Fig. 5A, 5B). Alternatively, in the presence of IL-12, IL-33 enhanced proliferation of WT Ly49H+ NK cells, but not Il1rl1−/− Ly49H+ NK cells (Fig. 5C, 5D).

FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

IL-33 enhances m157-dependent proliferation of Ly49H+ NK cells. CellTrace Violet–labeled splenocytes from WT and Il1rl1−/− mixed BM chimeric mice were cocultured with RMA or m157-transfected RMA cells in the absence or presence of IL-33 and/or IL-12. Percentages of divided Ly49H+ NK cells and the number of Ly49H+ NK cells in the cultures with or without IL-33 in the absence (A and B) or presence of IL-12 (C and D) are shown. Data are representative of two experiments (n = 3–4 in each stimulation). *p < 0.05, ***p < 0.005.

Discussion

The quantity of bioactive IL-33 is transcriptionally and posttranslationally regulated (12, 14). IL-33 transcription is induced by poly(I:C), an agonist of TLR3, which is essential in the innate immune defense against MCMV (22, 23). IL-33 is released by tissue damage or infection and subsequently cleaved into the biological active form by proteases released during inflammation (12). A previous study using an MCMV strain encoding GFP has demonstrated that MCMV infects FRCs and spreads in the spleen within 48 h p.i. (24). Interestingly, NK cells migrate to the white pulp of the spleen and are in contact with FRCs within the T cell area by 24 h after MCMV infection, prior to the expansion of Ly49H+ NK cells (25). Taken together, a high concentration of bioactive IL-33 at the local interface of NK cells with stromal cells would ensure efficient ST2 signaling in NK cells, which may contribute to the preferential expansion of Ly49H+ NK cells.

An IL-12/STAT4 signaling pathway is critical for both expansion and memory generation of NK cells in response to MCMV infection and alloantigen stimulation (6, 11). Unlike IL-12, the IL-33/ST2 signaling pathway augments the expansion of Ly49H+ NK cells, but it is not required for differentiation into memory cells. Although IL-33 synergizes with IL-12 for IFN-γ production by NK cells in vitro (15, 16), production of IFN-γ by NK cells in vivo early after MCMV infection does not require IL-33 or ST2, indicating that other cytokines produced during infection might compensate. Moreover, previously we demonstrated that Ly49H+ NK cells do not require IFN-γ to undergo expansion during MCMV infection (11), suggesting that the robust proliferation of NK cells requires IL-12–dependent signals and is enhanced by IL-33–dependent signals, but not IFN-γ–mediated signaling. Both IL-12–deficient and STAT4-deficient Ly49H+ NK cells have a severe defect in expansion during MCMV infection (11), whereas an IL-33/ST2 signaling deficiency has a lesser impact. IL-18 and IL-1β, which are other members of the IL-1 cytokine family, are known to synergize with IL-12 for IFN-γ production by NK cells in vitro and in vivo (15, 16, 26). A recent study has demonstrated that an IL-18/IL-18R signaling axis is required for the optimal IFN-γ production, expansion, and memory differentiation of Ly49H+ NK cells during MCMV infection (27). The authors show that MyD88-deficient Ly49H+ NK cells exhibit the same defects as IL-18R–deficient Ly49H+ NK cells (27). In contrast, IL-1R–deficient Ly49H+ NK cells normally expand and differentiate into memory NK cells after the infection (27). In the present study, ST2-deficient Ly49H+ NK cells exhibit impairment in MCMV-specific expansion of naive and memory Ly49H+ NK cells, but neither in IFN-γ production nor in differentiation into memory NK cells. Interestingly, IL-18R signaling is dispensable for the secondary expansion of memory Ly49H+ NK cells when rechallenged with MCMV. These results suggest that IL-33 is released by damaged cells in the early phase of MCMV infection and that ST2 signaling transiently enhances MyD88 signaling to augment the proliferation of naive and memory Ly49H+ NK cells, whereas IL-18 more broadly impacts NK cell responses in the course of MCMV infection.

Our findings indicate that multiple cytokines and their downstream signaling pathways differentially modulate the adaptive immune features of NK cells. Further studies of spatiotemporal regulation of cytokine production, as well as the adaptor molecules through which cytokine receptors signal, will be required to understand fully the molecular mechanisms underlying the differentiation of memory NK cells.

Disclosures

The authors have no financial conflicts of interest.

Acknowledgments

We thank the Lanier laboratory, Mehrdad Matloubian, and Ari Molofsky (University of California, San Francisco) for comments and discussions and Dr. Rich Locksley for mice and reagents.

Footnotes

  • The work was supported by National Institutes of Health Grant AI068129. L.L.L. is an American Cancer Society Professor, and the Japan Society for the Promotion of Science supports T.N.

  • Abbreviations used in this article:

    BM
    bone marrow
    FRC
    fibroblastic reticular cell
    LEC
    lymphatic endothelial cell
    MCMV
    mouse CMV
    p.i.
    postinfection
    WT
    wild-type.

  • Received February 20, 2015.
  • Accepted April 6, 2015.
  • Copyright © 2015 by The American Association of Immunologists, Inc.

References

  1. ↵
    1. Lanier L. L.
    2005. NK cell recognition. Annu. Rev. Immunol. 23: 225–274.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Cooper M. A.,
    2. J. M. Elliott,
    3. P. A. Keyel,
    4. L. Yang,
    5. J. A. Carrero,
    6. W. M. Yokoyama
    . 2009. Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. USA 106: 1915–1919.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Min-Oo G.,
    2. Y. Kamimura,
    3. D. W. Hendricks,
    4. T. Nabekura,
    5. L. L. Lanier
    . 2013. Natural killer cells: walking three paths down memory lane. Trends Immunol. 34: 251–258.
    OpenUrlCrossRefPubMed
    1. O’Leary J. G.,
    2. M. Goodarzi,
    3. D. L. Drayton,
    4. U. H. von Andrian
    . 2006. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat. Immunol. 7: 507–516.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Sun J. C.,
    2. J. N. Beilke,
    3. L. L. Lanier
    . 2009. Adaptive immune features of natural killer cells. Nature 457: 557–561.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Nabekura T.,
    2. L. L. Lanier
    . 2014. Antigen-specific expansion and differentiation of natural killer cells by alloantigen stimulation. J. Exp. Med. 211: 2455–2465.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Foley B.,
    2. S. Cooley,
    3. M. R. Verneris,
    4. J. Curtsinger,
    5. X. Luo,
    6. E. K. Waller,
    7. C. Anasetti,
    8. D. Weisdorf,
    9. J. S. Miller
    . 2012. Human cytomegalovirus (CMV)-induced memory-like NKG2C+ NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J. Immunol. 189: 5082–5088.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Lopez-Vergès S.,
    2. J. M. Milush,
    3. B. S. Schwartz,
    4. M. J. Pando,
    5. J. Jarjoura,
    6. V. A. York,
    7. J. P. Houchins,
    8. S. Miller,
    9. S. M. Kang,
    10. P. J. Norris,
    11. et al
    . 2011. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 108: 14725–14732.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Arase H.,
    2. E. S. Mocarski,
    3. A. E. Campbell,
    4. A. B. Hill,
    5. L. L. Lanier
    . 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296: 1323–1326.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Nabekura T.,
    2. M. Kanaya,
    3. A. Shibuya,
    4. G. Fu,
    5. N. R. Gascoigne,
    6. L. L. Lanier
    . 2014. Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. Immunity 40: 225–234.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Sun J. C.,
    2. S. Madera,
    3. N. A. Bezman,
    4. J. N. Beilke,
    5. M. H. Kaplan,
    6. L. L. Lanier
    . 2012. Proinflammatory cytokine signaling required for the generation of natural killer cell memory. J. Exp. Med. 209: 947–954.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Cayrol C.,
    2. J. P. Girard
    . 2014. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr. Opin. Immunol. 31: 31–37.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Pichery M.,
    2. E. Mirey,
    3. P. Mercier,
    4. E. Lefrancais,
    5. A. Dujardin,
    6. N. Ortega,
    7. J. P. Girard
    . 2012. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33–LacZ gene trap reporter strain. J. Immunol. 188: 3488–3495.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Palmer G.,
    2. C. Gabay
    . 2011. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 7: 321–329.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Bourgeois E.,
    2. L. P. Van,
    3. M. Samson,
    4. S. Diem,
    5. A. Barra,
    6. S. Roga,
    7. J. M. Gombert,
    8. E. Schneider,
    9. M. Dy,
    10. P. Gourdy,
    11. et al
    . 2009. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur. J. Immunol. 39: 1046–1055.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Smithgall M. D.,
    2. M. R. Comeau,
    3. B. R. Yoon,
    4. D. Kaufman,
    5. R. Armitage,
    6. D. E. Smith
    . 2008. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20: 1019–1030.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Sesti-Costa R.,
    2. G. K. Silva,
    3. J. L. Proença-Módena,
    4. D. Carlos,
    5. M. L. Silva,
    6. J. C. Alves-Filho,
    7. E. Arruda,
    8. F. Y. Liew,
    9. J. S. Silva
    . 2013. The IL-33/ST2 pathway controls coxsackievirus B5-induced experimental pancreatitis. J. Immunol. 191: 283–292.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Hoshino K.,
    2. S. Kashiwamura,
    3. K. Kuribayashi,
    4. T. Kodama,
    5. T. Tsujimura,
    6. K. Nakanishi,
    7. T. Matsuyama,
    8. K. Takeda,
    9. S. Akira
    . 1999. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J. Exp. Med. 190: 1541–1548.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Fodil-Cornu N.,
    2. S. H. Lee,
    3. S. Belanger,
    4. A. P. Makrigiannis,
    5. C. A. Biron,
    6. R. M. Buller,
    7. S. M. Vidal
    . 2008. Ly49h-deficient C57BL/6 mice: a new mouse cytomegalovirus-susceptible model remains resistant to unrelated pathogens controlled by the NK gene complex. J. Immunol. 181: 6394–6405.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Bakker A. B.,
    2. R. M. Hoek,
    3. A. Cerwenka,
    4. B. Blom,
    5. L. Lucian,
    6. T. McNeil,
    7. R. Murray,
    8. L. H. Phillips,
    9. J. D. Sedgwick,
    10. L. L. Lanier
    . 2000. DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity 13: 345–353.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Fletcher A. L.,
    2. D. Malhotra,
    3. S. E. Acton,
    4. V. Lukacs-Kornek,
    5. A. Bellemare-Pelletier,
    6. M. Curry,
    7. M. Armant,
    8. S. J. Turley
    . 2011. Reproducible isolation of lymph node stromal cells reveals site-dependent differences in fibroblastic reticular cells. Front. Immunol. 2: 35.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Polumuri S. K.,
    2. G. G. Jayakar,
    3. K. A. Shirey,
    4. Z. J. Roberts,
    5. D. J. Perkins,
    6. P. M. Pitha,
    7. S. N. Vogel
    . 2012. Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J. Immunol. 189: 50–60.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Tabeta K.,
    2. P. Georgel,
    3. E. Janssen,
    4. X. Du,
    5. K. Hoebe,
    6. K. Crozat,
    7. S. Mudd,
    8. L. Shamel,
    9. S. Sovath,
    10. J. Goode,
    11. et al
    . 2004. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 101: 3516–3521.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Hsu K. M.,
    2. J. R. Pratt,
    3. W. J. Akers,
    4. S. I. Achilefu,
    5. W. M. Yokoyama
    . 2009. Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. J. Gen. Virol. 90: 33–43.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Grégoire C.,
    2. C. Cognet,
    3. L. Chasson,
    4. C. A. Coupet,
    5. M. Dalod,
    6. A. Reboldi,
    7. J. Marvel,
    8. F. Sallusto,
    9. E. Vivier,
    10. T. Walzer
    . 2008. Intrasplenic trafficking of natural killer cells is redirected by chemokines upon inflammation. Eur. J. Immunol. 38: 2076–2084.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Hunter C. A.,
    2. R. Chizzonite,
    3. J. S. Remington
    . 1995. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J. Immunol. 155: 4347–4354.
    OpenUrlAbstract
  26. ↵
    1. Madera S.,
    2. J. C. Sun
    . 2015. Cutting edge: stage-specific requirement of IL-18 for antiviral NK cell expansion. J. Immunol. 194: 1408–1412.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 194 (12)
The Journal of Immunology
Vol. 194, Issue 12
15 Jun 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
IL-33 Receptor ST2 Amplifies the Expansion of NK Cells and Enhances Host Defense during Mouse Cytomegalovirus Infection
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IL-33 Receptor ST2 Amplifies the Expansion of NK Cells and Enhances Host Defense during Mouse Cytomegalovirus Infection
Tsukasa Nabekura, Jean-Philippe Girard, Lewis L. Lanier
The Journal of Immunology June 15, 2015, 194 (12) 5948-5952; DOI: 10.4049/jimmunol.1500424

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
IL-33 Receptor ST2 Amplifies the Expansion of NK Cells and Enhances Host Defense during Mouse Cytomegalovirus Infection
Tsukasa Nabekura, Jean-Philippe Girard, Lewis L. Lanier
The Journal of Immunology June 15, 2015, 194 (12) 5948-5952; DOI: 10.4049/jimmunol.1500424
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • IL-21/IL-21R Signaling Aggravated Respiratory Inflammation Induced by Intracellular Bacteria through Regulation of CD4+ T Cell Subset Responses
  • The Butyrate-Producing Bacterium Clostridium butyricum Suppresses Clostridioides difficile Infection via Neutrophil- and Antimicrobial Cytokine–Dependent but GPR43/109a-Independent Mechanisms
  • Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis
Show more INFECTIOUS DISEASE AND HOST RESPONSE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606